BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (26)
2023
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2021
-
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression
Blood Cancer Journal, Vol. 11, Núm. 7
-
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
The Lancet Oncology, Vol. 22, Núm. 5, pp. 727-736
2020
-
A reference map of the human binary protein interactome
Nature, Vol. 580, Núm. 7803, pp. 402-408
-
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
Leukemia, Vol. 34, Núm. 6, pp. 1599-1612
-
Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications
International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792
2019
-
Adiponectin accounts for gender differences in hepatocellular carcinoma incidence
Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1108-1119
-
DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains
Experimental Hematology, Vol. 72, pp. 9-13
-
Maximizing binary interactome mapping with a minimal number of assays
Nature Communications, Vol. 10, Núm. 1
-
Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma
Journal of Clinical Oncology
-
Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨
Journal of Clinical Oncology
2018
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia
American Journal of Hematology, Vol. 91, Núm. 10, pp. 978-983
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
-
Multidisciplinary approach of unresectable head and neck cancer
Head and Neck Cancer: Multimodality Management, Second Edition (Springer International Publishing), pp. 617-624
2015
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Nature Genetics, Vol. 47, Núm. 2, pp. 164-171